Healthcare Industry News: cervical spine fusion
News Release - April 24, 2008
Integra LifeSciences Announces the Addition of a New Size for Its Integra Mozaik Moldable PuttyPLAINSBORO, N.J., April 24, 2008 (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (NasdaqGS:IART ) announced today that the moldable putty configuration of Integra Mozaik(TM) Osteoconductive Scaffold is now available in a smaller configuration. The addition of the smaller configuration enables clinicians to use Integra Mozaik(TM) Osteoconductive Scaffold in even broader applications, where smaller sizes are appropriate, such as cervical spine fusion and other non-spine orthopedic procedures.
Integra Mozaik(TM) Osteoconductive Scaffold is designed to bridge gaps or fill voids in the skeletal structures of the spine, extremities, and pelvis and is available in two different configurations, a compression resistant strip and a moldable putty. It provides a framework for fusion by providing a compression resistance scaffold, as well as binding sites for cells and proteins; these elements are critical for the formation of new bone. When used with bone marrow aspirate from the patient, Integra Mozaik(TM) Osteoconductive Scaffold may replace the need to harvest bone from the patient's iliac crest, thus sparing the patient additional surgery and postoperative pain.
``Broadening the portfolio of Integra's orthobiologic products is a priority because it allows Integra to better address the needs of orthopedic surgeons and neurosurgeons,'' said Brian Larkin, President of Integra NeuroSciences.
The use of bone graft substitutes in spinal procedures, excluding synthetic bone morphogenetic proteins, represents an estimated $350 million market. In 2006, an estimated 450,000 spinal fusion procedures were performed in the United States, which included over 200,000 cervical spinal fusions. Additional opportunity exists in orthopedic reconstructive applications.
The Integra Mozaik(TM) Osteoconductive Scaffold is now distributed through the Integra OrthoBiologics network, which consists of approximately 45 distributors with over 300 sales representatives. The Integra OrthoBiologics distributor network is also supported by a direct sales team of 22 sales professionals. This distributor network already distributes Accell(R), Dynagraft(R), and OrthoBlast(R) demineralized bone matrices to the orthopedic market. The combination of the Integra Mozaik(TM) Osteoconductive Scaffold with the previously distributed demineralized bone matrices gives the distributor network a complete offering of bone graft substitutes for orthopedic surgeons and neurosurgeons.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. The company's products are used to treat millions of patients every year, primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery. Integra's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. http://www.Integra-LS.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Integra Mozaik(TM) Osteoconductive Scaffold, Accell(R), Dynagraft(R), and OrthoBlast(R) demineralized bone matrices. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading ``Risk Factors'' included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Source: Integra LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.